Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03020797
Recruitment Status : Terminated (1) Enrolment below study target and 2) too many subjects had early termination due to disease progression.)
First Posted : January 13, 2017
Last Update Posted : May 6, 2023
Eisai Inc.
Information provided by (Responsible Party):
Nurcan Gursoy, Stony Brook University

Brief Summary:
This is a pilot trial to test perampanel (Fycompa; Eisai, Inc.) in ALS patients. The investigators will focus on safety and preliminary signs of efficacy. Perampanel is approved by the FDA for treatment of seizures in patients with epilepsy. In this study, perampanel will be used off-label for adults with ALS at an oral medication dose on the low end of the recommended dose range for epilepsy. This study will consist of two treatments arms: perampanel and matching placebo randomized at a 1:1 ratio. Subjects will receive medication for 9 months.

Condition or disease Intervention/treatment Phase
Amyotrophic Lateral Sclerosis Drug: Perampanel Drug: Placebo Oral Tablet Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Actual Study Start Date : January 12, 2017
Actual Primary Completion Date : January 31, 2023
Actual Study Completion Date : February 8, 2023

Arm Intervention/treatment
Experimental: perampanel
perampanel 2mg QD for 2 weeks perampanel 4mg QD for 2 weeks perampanel 6mg QD for 2 weeks perampanel 8mg QD for 30 weeks
Drug: Perampanel
Other Name: Fycompa

Placebo Comparator: placebo
placebo 1 tablet QD for 2 weeks placebo 2 tablets QD for 2 weeks placebo 3 tablets QD for 2 weeks placebo 4 tablets QD for 2 weeks
Drug: Placebo Oral Tablet

Primary Outcome Measures :
  1. Incidence of treatment-emergent adverse events [ Time Frame: 9 months ]

Secondary Outcome Measures :
  1. Efficacy as measured by change in ALSFRS-R score (ALS functional rating scale-revised); [ Time Frame: 9 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. diagnosis of ALS
  2. first clinical weakness within past 3 years
  3. slow vital capacity >= 60% of predicted within 1 month of treatment
  4. may be on stable dose of riluzole for at least 30 days, or otherwise agree to not initiate riluzole for duration of the trial
  5. may be on stable dose of edaravone for at least 30 days, otherwise agree to not initiate edaravone for duration of the trial
  6. can travel to Stony Brook to receive medical care
  7. must have a monitor who can be contacted at regular intervals to report on subject's clinical/psychiatric status

Exclusion Criteria:

  1. use of tracheostomy or mechanical ventilation within last 3 months
  2. hepatic insufficiency or abnormal liver function
  3. renal insufficiency
  4. clinically significant psychiatric disorder
  5. active malignancy
  6. history of HIV, clinically significant chronic hepatitis, or other active infection
  7. history of stomach or intestinal surgery or condition that could interfere with absorption, distribution, metabolism or secretion of study drug
  8. history of alcohol or substance abuse within 3 months prior to entry (subjects will be instructed to refrain from alcohol during the study)
  9. use of strong cytochrome P4503A inhibitors or inducers, anticonvulsants or other drugs known to interact strongly with perampanel.
  10. pregnancy or lactation
  11. clinically significant medical condition (other than ALS) that would pose a risk to the subject if they were to participate
  12. know hypersensitivity to perampanel
  13. currently participating, or has participated in a study with an investigation or marketed compound within 3 months of entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03020797

Layout table for location information
United States, New York
Stony Brook University Medical Center
Stony Brook, New York, United States, 11794-8121
Sponsors and Collaborators
Stony Brook University
Eisai Inc.
Layout table for investigator information
Principal Investigator: Nurcan Gursoy, MD Stony Brook Medicine Dept. of Neurology
Layout table for additonal information
Responsible Party: Nurcan Gursoy, Clinical Assistant Professor, Stony Brook University Identifier: NCT03020797    
Other Study ID Numbers: Eisai-01
First Posted: January 13, 2017    Key Record Dates
Last Update Posted: May 6, 2023
Last Verified: May 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases